Difference between revisions of "Healthcare system reform"

From ScenarioThinking
Jump to navigation Jump to search
Line 4: Line 4:
==Developments in time==
==Developments in time==
===2010-2015===
===2010-2015===
At the end of first decade of new millennium, innovation in the healthcare system is primarily dominated by multinational companies. Regulators had generally seen their role as being limited to that of framing regulations to deal with potential safety and efficacy issues, and ensuring compliance with these regulations. Around 2010 after the 2008 financial crisis, instead of seeing themselves as passive responders to events, regulators began to see their role in a much more proactive way. In line with “new governance” agendas and linked to globalisation
initiatives, discussions began to take place within regulatory bodies about their role in stimulating
changes in the processes and outcomes of health care innovation.


The challenge addressed was to ensure the continued safety, quality and efficacy of new drugs but to
During first decade of new millennium, innovation in the healthcare system is primarily dominated by multinational companies.The most important factor contributing to this long term resilience of the drug-based innovation model, and its dominant role in the development of health care systems, was the regulatory system. The primary markets, Europe and USA, have very lengthy, expensive and complex set of regulations which impose significant constraints on the innovation system for drugs thus making product to market process a lengthy and costly process.  
do this within a system that was responsive to the new challenges being presented by life science
innovation. There was a profound shift in the perceived nature of the problem of the failure rate of
new drugs in Phase 2 and particularly Phase 3 clinical trials. This had been seen as a failure of industry
innovation models but began to be seen more as a mismatch between:
* the nature of new biotechnology innovations;
* the nature of the companies that could best exploit these innovations;
* public and patient expectations of new drugs and treatments; and
* regulatory systems that were designed around 20th century models of drug development.
 
The new regulatory approach that began to emerge required creative and constructive thinking from
senior managers, regulators and analysts in life science and ICT industries, along with an enthusiasm
for collaboration across non-traditional boundaries.


===2015-2020===
===2015-2020===
===2020-2025===
===2020-2025===

Revision as of 16:49, 8 October 2009

Work under construction. In case you have any questions, additions or comments, please do not edit these pages, but you are more than welcome to contact us.

Scenario wherein the healthcare system is more integrated, shorter lines between pharma, medicine, insurance companies

Developments in time

2010-2015

During first decade of new millennium, innovation in the healthcare system is primarily dominated by multinational companies.The most important factor contributing to this long term resilience of the drug-based innovation model, and its dominant role in the development of health care systems, was the regulatory system. The primary markets, Europe and USA, have very lengthy, expensive and complex set of regulations which impose significant constraints on the innovation system for drugs thus making product to market process a lengthy and costly process.

2015-2020

2020-2025

Retrieved from "https://www.scenariothinking.org/index.php?title=Healthcare_system_reform&oldid=31272"